



## PRESS RELEASE

**For Immediate Release**

### **New Independent Clinical Data Released on Corgenix AspirinWorks<sup>®</sup> Test Kit**

#### **Researchers Present Data Showing use of AspirinWorks to Determine the Effectiveness of Aspirin Therapy**

**DENVER, Colo. — July 11, 2007** — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced that publication of the latest clinical data for the AspirinWorks<sup>®</sup> Test which measures aspirin effectiveness, was released this week at the XXI<sup>st</sup> Congress of the International Society on Thrombosis and Hemostasis (ISTH) meeting in Geneva, Switzerland. Investigators reported that AspirinWorks is an effective way to measure urinary 11-Dehydro Thromboxane B<sub>2</sub>, a metabolite of thromboxane production, the target of aspirin therapy.

Research results were reported by independent groups from Canada and Australia who evaluated the AspirinWorks test in normal individuals, patients undergoing percutaneous coronary intervention (PTCA), and patients suffering from peripheral arterial disease (PAD). This study group is particularly significant because it is estimated that over 700,000 PTCA procedures are performed annually in the United States alone, and the American Heart Association estimates that PAD affects between 12 and 20% of Americans age 65 or older.

Other clinical research announced at the ISTH meeting in Geneva included reports that elevated urinary 11-Dehydro Thromboxane B<sub>2</sub> levels in heart failure patients indicates persistent platelet activation, while aspirin therapy significantly reduced these levels. Of greatest interest at the meeting was the finding that diabetics with coronary artery disease (CAD) demonstrate a higher incidence of aspirin resistance with 81 mg aspirin therapy than non-diabetics, as measured by urinary 11-Dehydro Thromboxane B<sub>2</sub> levels.

“Clinical reports from the ISTH meeting continue to document independent patient variation in response to aspirin therapy,” said Corgenix’ Clinical Affairs Director Gordon Ens. “The AspirinWorks test is a direct measurement of in vivo thromboxane production (aspirin’s target) allowing physicians to individualize their patient’s therapy.”

Investigators at this year’s ISTH meeting also noted that the new Corgenix AspirinWorks product, for the first time, enables potential standardization between laboratories, a problem with previous testing technologies.

“Release of this new data crosses another important milestone for our AspirinWorks product,” said Douglass Simpson, Corgenix’ President and Chief Executive Officer. “We are pleased to see this new data and believe that new clinical findings from additional studies scheduled for release later this year will be used to further validate the utility of AspirinWorks. We fully anticipate this product will become the standard of care worldwide.”

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail [techsupport@aspirinworks.com](mailto:techsupport@aspirinworks.com). More information is also available at [www.aspirinworks.com](http://www.aspirinworks.com).

### **About Corgenix Medical Corporation**

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at [www.corgenix.com](http://www.corgenix.com).

*Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.*

Company Contact:  
Corgenix Medical Corp.  
William Critchfield, Senior VP and CFO  
Phone: 303-453-8903  
Email: [wcritchfield@corgenix.com](mailto:wcritchfield@corgenix.com)

Investor Contact:  
The Investor Relations Group  
Dian Griesel/ Erika Moran  
Phone: 212-825-3210  
Fax: 212-825-3229

Media Contact:  
Dan Snyders  
Vice President, Public Relations Supervisor

Armada Medical Marketing  
Phone: 303-623-1190 x 230  
Fax: 303-623-1191  
[dan@armadamedical.com](mailto:dan@armadamedical.com)